Emcure FY26 Revenue Crosses $1 Billion, Grows 16.6%

Emcure Pharmaceuticals reported audited FY26 results, exceeding revenue guidance with 16.6% growth to cross the US$1 billion milestone.
International business was the key growth driver, up 22% YoY and contributing 60% of Q4 revenue, while domestic growth was 10%.
The company expanded EBITDA margins by 83 bps to 19.4% and improved adjusted PAT by over 40% through productivity enhancements.
Strategic highlights include new partnerships with Novo Nordisk and Roche, full consolidation of Zuventus, and progress in the R&D pipeline.